VYDUO

ANDA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN | A210596 | PRINSTON PHARMACEUTICAL INC

1 strength0 unique patents0 unique exclusivities

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Nov 28, 2022	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 5MG BASE;80MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Sep 19, 2022

No patent or exclusivity listings for this strength.